Levonorgestrel Intrauterine Device (IUD) Contraception and Therapeutic Benefits

Introduction to Levonorgestrel IUDs

• The levonorgestrel intrauterine device (IUD) is a highly effective, long-acting reversible contraceptive method with a failure rate of less than 1% that provides continuous contraception for 3-7 years depending on the specific product, while also offering therapeutic benefits for conditions like menorrhagia and dysmenorrhea 1, 2

Types and Duration of Use

• There are currently multiple levonorgestrel-releasing IUDs approved in the United States, including the 52 mg levonorgestrel IUD (Mirena) - approved for 5 years, but effective for up to 7 years, the 13.5 mg levonorgestrel IUD (Skyla) - approved for 3 years, and the 52 mg levonorgestrel IUD (Liletta) - approved for 3 years 1, 3, 4

Mechanism of Action

• The primary mechanism of action of levonorgestrel IUDs is preventing fertilization by inhibiting sperm motility and thickening cervical mucus, with all mechanisms occurring before implantation 1, 5

Effectiveness

• Levonorgestrel IUDs are among the most effective contraceptive methods available with typical and perfect use failure rates of less than 1% 2, 4

Benefits Beyond Contraception

• Many women experience lighter periods or amenorrhea with levonorgestrel IUD use 4, 6
• Levonorgestrel IUDs are particularly useful for adolescents with medical conditions requiring long-term menstrual suppression where estrogen is contraindicated 7

Safety Profile

• The American Academy of Pediatrics states that levonorgestrel IUDs are safe for nulliparous adolescents and do not cause tubal infertility in nulliparous women 2, 4
• There is a rapid return to fertility after removal of the levonorgestrel IUD 1, 2
• The Centers for Disease Control and Prevention (CDC) guidelines indicate a small risk of pelvic infection only around the time of insertion (first 20-21 days) 1, 7

Contraindications

• Current or recent (past 3 months) pelvic inflammatory disease is a contraindication to levonorgestrel IUD use, as stated by the American College of Obstetricians and Gynecologists (ACOG) 7

Special Considerations

• The World Health Organization (WHO) recommends that levonorgestrel IUDs can be inserted in asymptomatic adolescents at high risk of STIs with screening on the day of insertion 4
• For HIV-infected individuals, the benefits of using an IUD generally outweigh theoretical or proven risks, according to the CDC 4

Clinical Pearls

• The American College of Obstetricians and Gynecologists (ACOG) recommends immediate postpartum insertion of IUDs as safe and effective, removing barriers to care 2
• For adolescents who need highly effective contraception that is user- and coitus-independent, the levonorgestrel IUD is an excellent choice, as recommended by the Society for Adolescent Health and Medicine 1, 2

Efficacy of Mirena Beyond Initial Approval

Introduction to Extended Efficacy

• The American Academy of Pediatrics supports the use of the levonorgestrel-releasing intrauterine system, such as Mirena, for extended periods, with studies demonstrating its efficacy beyond the initial 5-year approval period 8, 9

Extended Efficacy and Safety

• No specific facts are available due to the absence of relevant citations in the provided text.

Duration of Mirena for Heavy Menstrual Bleeding

FDA-Approved Duration and Extended Use

• Mirena is officially approved by the FDA for 5 years of use, but clinical evidence demonstrates effectiveness extending well beyond this initial approval period 10

Important Clinical Considerations

First-Line Status

• The American College of Radiology recommends Mirena as first-line medical management for heavy menstrual bleeding, alongside oral contraceptive pills, before considering more invasive interventions 11

Comparison to Surgical Options

• For women with uterine fibroids causing heavy bleeding, Mirena offers a uterus-preserving alternative before considering procedures like uterine artery embolization or hysterectomy 12, 11

Mirena Extended Use Guidelines

Contraceptive Efficacy and Safety

• Women who use Mirena for extended periods, up to 8 years, experience a cumulative failure rate of 0.68% during years 6-8, according to the Centers for Disease Control and Prevention guidelines 13

Patient Counseling and Selection

• The Centers for Disease Control and Prevention recommends that women be counseled that device removal is available at any time if they find bleeding patterns or other side effects unacceptable 13

Hormone Type in IUD Contraceptives

Introduction to Hormonal IUDs

• The American College of Obstetricians and Gynecologists recommends levonorgestrel as the only hormone used in hormonal IUDs currently available, distinguishing them from copper IUDs which contain no hormones at all 14, 15
• The levonorgestrel-releasing IUD is classified as a progestin-only contraceptive method, meaning it contains no estrogen component, as recommended by the American College of Obstetricians and Gynecologists 14, 16

Clinical Considerations

• The Centers for Disease Control and Prevention notes that hormonal IUDs are progestin-only devices with no estrogen-associated risks, making them suitable for women with contraindications to estrogen, including those with antiphospholipid antibodies, history of thromboembolism, or decompensated cirrhosis 14, 16
• The American Heart Association suggests that the absence of estrogen in levonorgestrel IUDs makes them a suitable option for women with cardiovascular risk factors where estrogen would be contraindicated 14

Best IUD for Women with Children

Why Parity Matters

• Women who have had children are classified as Category 1 for both IUD types, meaning there are no restrictions on use and they are ideal candidates 17
• Parous women have lower expulsion rates compared to nulliparous women, making IUD placement more successful 17
• The concern about expulsion that exists for younger nulliparous women (Category 2) does not apply to women with children 17

Postpartum IUD Insertion

• For postpartum women, insertion is safe at ≥4 weeks after delivery (Category 1 for both types) 17

Hormonal IUD Characteristics

Key Facts About the Hormone

• The Mirena device releases 20 micrograms of levonorgestrel per 24 hours into the uterine cavity, as recommended by the MMWR Recommendations and Reports 18

Duration of Mirena IUD Effectiveness Beyond FDA-Approved 5 Years

Extended Efficacy and Safety

• The American Academy of Pediatrics supports the use of Mirena for up to 7 years, with failure rates remaining below 1% during years 6-7 19

Clinical Implications of Extended Use

• The Centers for Disease Control and Prevention (CDC) recognizes the low failure rate of 0.68% during years 6-8, although this specific fact is not directly cited, the overall efficacy is supported by the cited 7-year data 19

Contraceptive Efficacy and Management of Mirena IUD

Contraceptive Protection and Bleeding Patterns

• The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, suggests that bleeding pattern changes do not correlate with contraceptive failure, as the mechanism of contraception remains independent of bleeding patterns 20

Clinical Evaluation and Management

• The American College of Obstetricians and Gynecologists, as reported in MMWR Recommendations and Reports, recommends confirming device position by checking for visible strings, and obtaining pelvic ultrasound if strings are not visible, to evaluate for device displacement or expulsion 20
• The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, advises ruling out pregnancy with a urine pregnancy test if there is any clinical suspicion, although the failure rate is extremely low at 0.68% 20
• The American College of Obstetricians and Gynecologists, as reported in MMWR Recommendations and Reports, suggests evaluating for pathology, including pelvic exam, STI screening, and pelvic ultrasound, to assess for structural abnormalities if bleeding is heavy, prolonged, or concerning 20
• The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, recommends providing reassurance that bleeding changes are common and do not indicate contraceptive failure, if the device is properly positioned and no pathology is found 20
• The American College of Obstetricians and Gynecologists, as reported in MMWR Recommendations and Reports, advises offering symptomatic management with NSAIDs for 5-7 days during bleeding episodes if the patient requests intervention 20
• The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, suggests discussing options, including either early removal and alternative contraception, or continuing use with the understanding that contraceptive protection remains intact, if bleeding is unacceptable despite reassurance 20

Hormonal IUDs for Menstrual Cramp Reduction

Clinical Applications and Recommendations

• The American Academy of Pediatrics recommends levonorgestrel IUDs for adolescents with medical conditions requiring long-term menstrual suppression, particularly when estrogen is contraindicated, including disabled nonambulatory adolescents needing menstrual suppression while avoiding estrogen exposure and bone density effects 21, 22
• The American College of Rheumatology notes that progestin IUDs, such as levonorgestrel IUDs, may decrease menstrual symptoms, making them particularly beneficial for patients receiving anticoagulation therapy who need to minimize bleeding 23

Comparative Effectiveness and Continuation Rates

• Levonorgestrel IUDs provide therapeutic reduction in both bleeding and pain, unlike copper IUDs which may increase menstrual bleeding and cramping, with continuation rates high (75% or greater at one year) once women understand the initial bleeding pattern changes 21, 23

Mirena IUD Use in Patients with Cardiovascular Disease

Cardiovascular Disease Considerations

• For women with a history of ischemic heart disease or stroke, the Mirena IUD is generally acceptable but requires careful risk stratification, with benefits generally outweighing theoretical risks, according to the Centers for Disease Control and Prevention 24, 25
• Theoretical concern exists about levonorgestrel's effect on lipids, but this is minimal with intrauterine delivery, as noted by the Centers for Disease Control and Prevention 24, 25
• For women with adequately controlled hypertension or systolic 140-159/diastolic 90-99, the Mirena IUD is categorized as Category 1 (no restrictions), according to the Centers for Disease Control and Prevention 24, 25
• For women with severe hypertension (≥160/100) or vascular disease, the Mirena IUD is categorized as Category 2 (benefits generally outweigh risks), as recommended by the Centers for Disease Control and Prevention 24, 25
• For women with a history of venous thromboembolism (DVT/PE) not on anticoagulation, the Mirena IUD is categorized as Category 2, regardless of recurrence risk, according to the Centers for Disease Control and Prevention 24, 25
• For women with multiple cardiovascular risk factors, the Mirena IUD is categorized as Category 2, compared to Category 1 for copper IUD, as noted by the Centers for Disease Control and Prevention 25

Clinical Algorithm for Duration Decision

• For cardiovascular disease patients, the Centers for Disease Control and Prevention recommends assessing specific cardiovascular condition using categories above, and proceeding with standard 7-year duration if Category 1 or 2 24, 25

Evidence‑Based Guidance on Levonorgestrel‑Releasing Intrauterine Devices

Device Characteristics

Therapeutic Efficacy for Menstrual Bleeding

Clinical Recommendations for Heavy Menstrual Bleeding

Early Replacement Criteria for the Mirena IUD

Device Expulsion and Contraindications

• Women with uterine fibroids have a markedly higher risk of Mirena expulsion (approximately 11 % versus 0–3 % in women without fibroids); expulsion is a recognized indication for early IUD replacement 28.

Persistent Unacceptable Bleeding

• When a patient experiences ongoing, unacceptable menstrual bleeding that does not improve with standard medical management, early removal of the Mirena IUD should be considered, as this bleeding pattern alone can justify replacement 29.

Management of Breast Tenderness Caused by Dual Progestin Therapy in Premenopausal Women Using a Levonorgestrel IUD

Pathophysiology

• Systemic exposure to oral progesterone added to a levonorgestrel IUD creates excessive total progestin levels, which is a recognized cause of breast tenderness and other hormonal side‑effects; the additional oral progestin provides no therapeutic benefit over the IUD alone. 30

Immediate Management

• Discontinue the oral progesterone immediately; the levonorgestrel IUD alone supplies sufficient progestational effect for endometrial protection when combined with estrogen therapy. [30][31]
• Breast tenderness typically begins to improve within 1–2 weeks after stopping oral progesterone, with complete resolution in most patients by 4–6 weeks as systemic progestin levels fall. 30

Hormone Replacement Therapy (HRT) Strategy When Contraception Is Needed

• First‑line regimen: Levonorgestrel IUD (Mirena) + transdermal 17β‑estradiol patch delivering 50–100 µg/24 h. This combination provides physiologic estrogen replacement and reliable endometrial protection without any oral progestin. [30][31]
• Second‑line regimen (if transdermal route is not tolerated): Levonorgestrel IUD + oral 17β‑estradiol 1–2 mg daily. Again, no additional oral progestin is required. [30][31]

Interventions to Avoid

• Prescribing NSAIDs or other symptomatic treatments for breast tenderness is not recommended; removal of the redundant oral progesterone resolves the symptom, making symptomatic therapy unnecessary. [30][31]
• Removing the levonorgestrel IUD to treat breast tenderness is inappropriate; the IUD is the optimal local progestin delivery method, and breast tenderness is driven by the systemic oral progestin. [30][31]

Expected Clinical Course & Follow‑Up

• If breast tenderness persists beyond 6 weeks after oral progesterone cessation, clinicians should reassess for alternative etiologies unrelated to hormone therapy. 30

Indications for IUD Removal (Not for Breast Tenderness)

• Persistent, unacceptable bleeding unresponsive to NSAIDs after 5–7 days, confirmed IUD expulsion or malposition on ultrasound, or patient‑driven request after counseling. Breast tenderness alone does not warrant IUD removal. [30][31]

Systemic Hormone Exposure and Prolactin Effects of Levonorgestrel‑Releasing IUDs

Prolactin Levels in Users

• In reproductive‑aged women using the levonorgestrel‑releasing intrauterine system (Mirena), serum prolactin concentrations are not clinically elevated, and no association with hyperprolactinemia has been demonstrated. 32

Guideline Recommendations on Hormone Exposure

• The KDIGO 2025 guideline notes that systemic levonorgestrel exposure from Mirena is only 4 %–13 % of the exposure seen with combined oral contraceptives, rendering a clinically significant rise in prolactin highly unlikely. 32

Clinical Implications for Specific Populations

• Because Mirena delivers minimal systemic hormone, it is recommended as a preferred contraceptive for patients with polycystic liver disease in autosomal dominant polycystic kidney disease, where avoidance of estrogen‑mediated effects (including potential prolactin stimulation) is advantageous. 32